Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Pfs230D1-CRM197 With R21 in Matrix-M1 in Healthy African School Children and Adults
NCT07147400Phase 2Active, not recruiting
- Sponsor
- Serum Institute of India
- Start
- Aug 2025
- Primary completion
- Nov 2027
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Pfs230D1-CRM197 in malaria (10 cohorts), sponsored by Serum Institute of India. Primary endpoints: Number of Participants with Immediate adverse events at 30 minutes, Number of Participants with solicited local adverse events at 7 days and 6 more. Started Aug 2025; status: active, not recruiting.
02
Drugs
Pfs230D1-CRM197
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07147400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07147400.